These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 12213884)

  • 1. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo.
    Rubin J; Ackert-Bicknell CL; Zhu L; Fan X; Murphy TC; Nanes MS; Marcus R; Holloway L; Beamer WG; Rosen CJ
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4273-9. PubMed ID: 12213884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells.
    Fan X; Roy E; Zhu L; Murphy TC; Ackert-Bicknell C; Hart CM; Rosen C; Nanes MS; Rubin J
    Endocrinology; 2004 Feb; 145(2):751-9. PubMed ID: 14563699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
    Lee SK; Lorenzo JA
    Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells.
    Hofbauer LC; Shui C; Riggs BL; Dunstan CR; Spelsberg TC; O'Brien T; Khosla S
    Biochem Biophys Res Commun; 2001 Jan; 280(1):334-9. PubMed ID: 11162519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
    Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
    Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway.
    Kanematsu M; Yoshimura K; Takaoki M; Sato A
    Bone; 2002 Apr; 30(4):553-8. PubMed ID: 11934645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression.
    Kim YH; Kim GS; Jeong-Hwa B
    Exp Mol Med; 2002 May; 34(2):145-51. PubMed ID: 12085990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
    Fazzalari NL; Kuliwaba JS; Atkins GJ; Forwood MR; Findlay DM
    J Bone Miner Res; 2001 Jun; 16(6):1015-27. PubMed ID: 11393778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
    Palmqvist P; Persson E; Conaway HH; Lerner UH
    J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts.
    Viereck V; Gründker C; Friess SC; Frosch KH; Raddatz D; Schoppet M; Nisslein T; Emons G; Hofbauer LC
    J Bone Miner Res; 2005 Nov; 20(11):2036-43. PubMed ID: 16234977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage.
    Komuro H; Olee T; Kühn K; Quach J; Brinson DC; Shikhman A; Valbracht J; Creighton-Achermann L; Lotz M
    Arthritis Rheum; 2001 Dec; 44(12):2768-76. PubMed ID: 11762937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen.
    Bord S; Frith E; Ireland DC; Scott MA; Craig JI; Compston JE
    Br J Haematol; 2004 Jul; 126(2):244-51. PubMed ID: 15238146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
    Swanson C; Lorentzon M; Conaway HH; Lerner UH
    Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTH differentially regulates expression of RANKL and OPG.
    Huang JC; Sakata T; Pfleger LL; Bencsik M; Halloran BP; Bikle DD; Nissenson RA
    J Bone Miner Res; 2004 Feb; 19(2):235-44. PubMed ID: 14969393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
    Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
    J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.
    Gori F; Hofbauer LC; Dunstan CR; Spelsberg TC; Khosla S; Riggs BL
    Endocrinology; 2000 Dec; 141(12):4768-76. PubMed ID: 11108292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.